JP2022166014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022166014A5 JP2022166014A5 JP2022118437A JP2022118437A JP2022166014A5 JP 2022166014 A5 JP2022166014 A5 JP 2022166014A5 JP 2022118437 A JP2022118437 A JP 2022118437A JP 2022118437 A JP2022118437 A JP 2022118437A JP 2022166014 A5 JP2022166014 A5 JP 2022166014A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- biomarker
- caspase
- sample
- therapeutic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 36
- 238000000034 method Methods 0.000 claims 30
- 230000001225 therapeutic effect Effects 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 19
- 125000001188 haloalkyl group Chemical group 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000003107 substituted aryl group Chemical group 0.000 claims 12
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- -1 BIP Proteins 0.000 claims 8
- 239000013074 reference sample Substances 0.000 claims 7
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 6
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 6
- 108090000397 Caspase 3 Proteins 0.000 claims 6
- 108090000567 Caspase 7 Proteins 0.000 claims 6
- 102100029855 Caspase-3 Human genes 0.000 claims 6
- 102100038902 Caspase-7 Human genes 0.000 claims 6
- 102000004091 Caspase-8 Human genes 0.000 claims 6
- 108090000538 Caspase-8 Proteins 0.000 claims 6
- 102000004039 Caspase-9 Human genes 0.000 claims 6
- 108090000566 Caspase-9 Proteins 0.000 claims 6
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 claims 6
- 102100035419 DnaJ homolog subfamily B member 9 Human genes 0.000 claims 6
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 claims 6
- 102100021807 ER degradation-enhancing alpha-mannosidase-like protein 1 Human genes 0.000 claims 6
- 102100030013 Endoribonuclease Human genes 0.000 claims 6
- 102100030667 Eukaryotic peptide chain release factor subunit 1 Human genes 0.000 claims 6
- 101710175705 Eukaryotic peptide chain release factor subunit 1 Proteins 0.000 claims 6
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 claims 6
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 6
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 claims 6
- 101000804119 Homo sapiens DnaJ homolog subfamily B member 9 Proteins 0.000 claims 6
- 101000895701 Homo sapiens ER degradation-enhancing alpha-mannosidase-like protein 1 Proteins 0.000 claims 6
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 claims 6
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 claims 6
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 6
- 101000611643 Homo sapiens Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 claims 6
- 101000822339 Homo sapiens Protein transport protein Sec24D Proteins 0.000 claims 6
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 6
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims 6
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 6
- 102100040714 Protein phosphatase 1 regulatory subunit 15A Human genes 0.000 claims 6
- 102100022542 Protein transport protein Sec24D Human genes 0.000 claims 6
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 6
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 6
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 5
- 239000013068 control sample Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 230000004043 responsiveness Effects 0.000 claims 2
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- DOCFCULFTLNCRC-UHFFFAOYSA-N N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoro-2-(4-fluorophenyl)acetamide Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)CNC(C(C1=CC=C(C=C1)F)(F)F)=O)=O)=O DOCFCULFTLNCRC-UHFFFAOYSA-N 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000003319 supportive effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276700P | 2016-01-08 | 2016-01-08 | |
| US62/276,700 | 2016-01-08 | ||
| US201662404638P | 2016-10-05 | 2016-10-05 | |
| US62/404,638 | 2016-10-05 | ||
| JP2018535307A JP6880037B2 (ja) | 2016-01-08 | 2017-01-06 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2021077686A JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021077686A Division JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022166014A JP2022166014A (ja) | 2022-11-01 |
| JP2022166014A5 true JP2022166014A5 (enExample) | 2023-02-02 |
Family
ID=59274055
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535307A Active JP6880037B2 (ja) | 2016-01-08 | 2017-01-06 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2021077686A Active JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2022118437A Pending JP2022166014A (ja) | 2016-01-08 | 2022-07-26 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535307A Active JP6880037B2 (ja) | 2016-01-08 | 2017-01-06 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2021077686A Active JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10648983B2 (enExample) |
| EP (1) | EP3399980B1 (enExample) |
| JP (3) | JP6880037B2 (enExample) |
| KR (1) | KR20180095094A (enExample) |
| AU (1) | AU2017205170B2 (enExample) |
| CA (1) | CA3010801A1 (enExample) |
| ES (1) | ES3042541T3 (enExample) |
| IL (2) | IL296659A (enExample) |
| MX (1) | MX390772B (enExample) |
| WO (1) | WO2017120446A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| US10338077B2 (en) | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| EP3352756A1 (en) | 2015-09-25 | 2018-08-01 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| EP3728639B1 (en) | 2017-12-20 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of selection of an ire1-inhibitor therapy for patient suffering from cancer |
| CN112313236A (zh) * | 2018-03-30 | 2021-02-02 | 拜欧斯瑞克斯公司 | 噻吩并嘧啶酮化合物 |
| EP3796909A4 (en) * | 2018-05-23 | 2022-03-16 | Celgene Corporation | TREATMENT OF MULTIPLE MYELoma AND USE OF BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)-PIPERAZINE -1-YL)-3-FLUOROBENZONITRILE |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12466816B2 (en) | 2019-09-12 | 2025-11-11 | Shanghaitech University | Fused cyclic compound capable of degrading protein and use thereof |
| CA3156232A1 (en) * | 2019-10-28 | 2021-05-06 | Gang Lu | Use of biomarkers to predict clinical sensitivity to 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| BR112022007932A2 (pt) * | 2019-10-28 | 2022-07-12 | Celgene Corp | Métodos para tratamento de leucemia e uso de uma assinatura de células-tronco leucêmicas para predizer sensibilidade clínica a terapias |
| US11031119B2 (en) * | 2019-11-13 | 2021-06-08 | Cube Click, Inc. | Dental images processed with deep learning for national security |
| MX2022006133A (es) * | 2019-12-06 | 2022-06-17 | Celgene Corp | Procesos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin- 3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. |
| KR102311390B1 (ko) * | 2020-03-03 | 2021-10-13 | 이화여자대학교 산학협력단 | 교모세포종 예후예측용 조성물 |
| IL296557A (en) * | 2020-03-16 | 2022-11-01 | Celgene Corp | Combined treatment for acute myeloid leukemia |
| WO2021211742A1 (en) * | 2020-04-14 | 2021-10-21 | The General Hospital Corporation | Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction |
| KR20230028798A (ko) | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| PE20230847A1 (es) | 2020-09-23 | 2023-05-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| WO2022152822A1 (en) * | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Treatment of myc-driven cancers with gspt1 degraders |
| GB202104635D0 (en) * | 2021-03-31 | 2021-05-12 | Imperial College Innovations Ltd | Methods and compositions for identifying and treating GCN2-dependent cancers |
| TW202304882A (zh) * | 2021-04-07 | 2023-02-01 | 瑞士商妥瑞莫醫療公司 | 雜環衍生物、醫藥組成物及彼等於治療或改善癌症之用途 |
| EP4323349A1 (en) * | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
| KR102823538B1 (ko) | 2021-11-09 | 2025-06-23 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
| JP2024544507A (ja) | 2021-11-09 | 2024-12-03 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | グルタルイミド母核を有するイソインドリノン誘導体及びその用途 |
| CN114660289A (zh) * | 2022-03-03 | 2022-06-24 | 中山大学附属第三医院 | 肝癌标志物及其应用 |
| EP4508044A1 (en) * | 2022-04-14 | 2025-02-19 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
| US20240115557A1 (en) * | 2022-07-29 | 2024-04-11 | The Brigham And Women's Hospital, Inc. | Inhibitors of rna-guided nucleases and uses thereof |
| IL319564A (en) * | 2022-09-16 | 2025-05-01 | Univ Temple | BAG 3 methods and uses for treating cardiac amyloidosis |
| KR20240066904A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR20240066906A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR102570883B1 (ko) * | 2023-04-13 | 2023-08-29 | (주) 사이러스테라퓨틱스 | 신규한 gspt1 분해제 및 이의 용도 |
| WO2025164957A1 (ko) * | 2024-01-31 | 2025-08-07 | 남부대학교산학협력단 | 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1574740A (en) * | 1924-04-07 | 1926-02-23 | Raynor John Roscoe | Cutting device |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| JP3645903B2 (ja) | 1992-03-04 | 2005-05-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 比較ゲノムハイブリダイゼーション（ｃｇｈ） |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DK0839525T3 (da) | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
| ZA9711385B (en) | 1996-12-20 | 1999-06-18 | Takeda Chemical Industries Ltd | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| GB0103527D0 (en) | 2001-02-13 | 2001-03-28 | Eastman Kodak Co | Photographic developing composition and use thereof in the development of a photographic element |
| US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
| MX2007014537A (es) * | 2005-05-18 | 2008-02-12 | Wyeth Corp | Genes de la enfermedad de la leucemia y sus usos. |
| SG195613A1 (en) | 2008-10-29 | 2013-12-30 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer |
| CA2792872A1 (en) * | 2010-03-12 | 2011-09-15 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| WO2012135299A1 (en) * | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| CA2877736C (en) | 2012-06-29 | 2021-12-07 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
| WO2014179661A1 (en) * | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| US20160312292A1 (en) | 2013-12-06 | 2016-10-27 | Celgene Corporation | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| US10338077B2 (en) | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| JP2018525991A (ja) | 2015-08-12 | 2018-09-13 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| EP3352756A1 (en) | 2015-09-25 | 2018-08-01 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399979B9 (en) * | 2016-01-08 | 2023-10-04 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| CA3010794A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| IL262565B (en) * | 2016-06-06 | 2022-08-01 | Celgene Corp | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
-
2017
- 2017-01-06 EP EP17736415.5A patent/EP3399980B1/en active Active
- 2017-01-06 KR KR1020187022882A patent/KR20180095094A/ko not_active Ceased
- 2017-01-06 JP JP2018535307A patent/JP6880037B2/ja active Active
- 2017-01-06 IL IL296659A patent/IL296659A/en unknown
- 2017-01-06 MX MX2018008421A patent/MX390772B/es unknown
- 2017-01-06 US US15/400,766 patent/US10648983B2/en active Active
- 2017-01-06 CA CA3010801A patent/CA3010801A1/en active Pending
- 2017-01-06 ES ES17736415T patent/ES3042541T3/es active Active
- 2017-01-06 AU AU2017205170A patent/AU2017205170B2/en active Active
- 2017-01-06 WO PCT/US2017/012496 patent/WO2017120446A1/en not_active Ceased
-
2018
- 2018-07-03 IL IL260400A patent/IL260400B2/en unknown
-
2020
- 2020-04-03 US US16/840,299 patent/US11460471B2/en active Active
-
2021
- 2021-04-30 JP JP2021077686A patent/JP7113942B2/ja active Active
-
2022
- 2022-07-26 JP JP2022118437A patent/JP2022166014A/ja active Pending
- 2022-08-05 US US17/882,278 patent/US12474342B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022166014A5 (enExample) | ||
| JP2021121799A5 (enExample) | ||
| Prelaj et al. | Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program | |
| Finn et al. | Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study | |
| JP2017538104A5 (enExample) | ||
| US11207324B2 (en) | Treatment of HER2 positive cancers | |
| US20220062373A1 (en) | Methods for Modulating Macrophage Activity | |
| JP2019507721A5 (enExample) | ||
| US20230310455A1 (en) | Combination therapies for treatment of her2 cancer | |
| JP2018535951A5 (enExample) | ||
| HK1223557A1 (zh) | 用於治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂 | |
| CN114945369A (zh) | 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法 | |
| Janku et al. | Molecular profiling of tumor tissue and plasma cell-free DNA from patients with non-Langerhans cell histiocytosis | |
| Mitri et al. | TBCRC-010: phase I/II study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis | |
| Falini et al. | How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors | |
| JP2019502741A (ja) | がんを処置するための方法 | |
| JP2019507114A5 (enExample) | ||
| JP2019502708A5 (enExample) | ||
| BR112020020246A2 (pt) | Inibidores de cinase axl e uso dos mesmos | |
| JP2023508996A (ja) | Ｃｄｋ１２／１３阻害剤を用いる癌の処置 | |
| JP2022513255A (ja) | ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用 | |
| US20160045598A1 (en) | Combination Treatments with Sonic Hedgehog Inhibitors | |
| Dudek et al. | Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy | |
| TW202423445A (zh) | 英菲格拉替尼在治療胃癌和腺癌中的用途 | |
| JP2022553041A (ja) | Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法 |